Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash & Equivalents (2016 - 2025)

Cytokinetics (CYTK) has disclosed Cash & Equivalents for 16 consecutive years, with $122.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents changed N/A to $122.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $122.5 million for FY2025, N/A changed from the prior year.
  • Cash & Equivalents for Q4 2025 was $122.5 million at Cytokinetics, down from $225.5 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $225.5 million in Q3 2025, with the low at $37.2 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $100.4 million, with a median of $100.1 million recorded in 2023.
  • Peak annual rise in Cash & Equivalents hit 377.05% in 2025, while the deepest fall reached 60.66% in 2025.
  • Over 5 years, Cash & Equivalents stood at $112.7 million in 2021, then crashed by 40.37% to $67.2 million in 2022, then skyrocketed by 68.79% to $113.4 million in 2023, then crashed by 58.32% to $47.3 million in 2024, then soared by 159.23% to $122.5 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $122.5 million, $225.5 million, and $74.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.